Boron-Containing Compounds as Antimicrobial Agents to Tackle Drug-Resistant Bacteria

Abstract

Bacterial infections, especially those caused by drug-resistant bacterial pathogens, are crucial diseases that damage human health. In recent decades, several important boron-containing drugs have been marketed as anticancer agents or anti-infective adjuvants. Among them, vaborbactam revitalizes the antibacterial effects of meropenem against bacteria by inhibiting β-lactamases, opening a new field for addressing bacterial resistance. In this article, the chemical features of boron atoms and the typical antibacterial agents and adjuvants of boron-containing compounds are reviewed. In this work, boron-containing agents are classified into four categories according to their action mechanisms: β-lactamase inhibitors, leucyl-tRNA synthetase inhibitors, LexA self-cleavage inhibitors, and NorA efflux pump inhibitors. This review provides actionable insights for addressing the increasingly severe drug-resistant infections of bacterial pathogens.

Keywords

boron-containing compounds - bacterial infections - drug-resistant - antibacterial agents - adjuvants

^# These authors contributed equally to this work.

Publikationsverlauf

Eingereicht: 28. März 2024

Angenommen: 08. Oktober 2024

Artikel online veröffentlicht:
20. November 2024

• References

• 1 De Oliveira DMP, Forde BM, Kidd TJ. et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev 2020; 33 (03) e00181-e19
• 2 Fleming A. Onthe antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929; 10: 226-236
• 3 Cepas V, López Y, Muñoz E. et al. Relationship between biofilm formation and antimicrobial resistance in Gram-negative bacteria. Microb Drug Resist 2019; 25 (01) 72-79
• 4 Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013; 12 (05) 371-387
• 5 Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016; 529 (7586): 336-343
• 6 Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24 (01) 71-109
• 7 Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 2012; 12 (05) 527-534
• 8 Fernandes GFS, Denny WA, Dos Santos JL. Boron in drug design: recent advances in the development of new therapeutic agents. Eur J Med Chem 2019; 179: 791-804
• 9 Giovannuzzi S, Nikitjuka A, Pereira Resende BR. et al. Boron-containing carbonic anhydrases inhibitors. Bioorg Chem 2024; 143: 106976
• 10 Sabnis RW. Boron-containing pyrazole compounds as JAK inhibitors for treating inflammation, autoimmune diseases, and cancer. ACS Med Chem Lett 2022; 13 (10) 1554-1555
• 11 Ren J, Gao Y, Shi W. et al. Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy. Bioorg Med Chem 2022; 75: 117071
• 12 Scorei RI, Popa Jr R. Boron-containing compounds as preventive and chemotherapeutic agents for cancer. Anticancer Agents Med Chem 2010; 10 (04) 346-351
• 13 Chen M, Menon MC, Wang W. et al. HCK induces macrophage activation to promote renal inflammation and fibrosis via suppression of autophagy. Nat Commun 2023; 14 (01) 4297
• 14 Jia R, Zhang J, Zhang J. et al. Discovery of novel boron-containing n-substituted oseltamivir derivatives as anti-influenza virus agents for overcoming N1–H274Y oseltamivir-resistant. Molecules 2022; 27 (19) 6426
• 15 Song S, Gao P, Sun L. et al. Recent developments in the medicinal chemistry of single boron atom-containing compounds. Acta Pharm Sin B 2021; 11 (10) 3035-3059
• 16 Newman H, Krajnc A, Bellini D. et al. High-throughput crystallography reveals boron-containing inhibitors of a penicillin-binding protein with di- and tricovalent binding modes. J Med Chem 2021; 64 (15) 11379-11394
• 17 Gorovoy AS, Gozhina OV, Svendsen JS. et al. Boron-containing peptidomimetics–a novel class of selective anti-tubercular drugs. Chem Biol Drug Des 2013; 81 (03) 408-413
• 18 Narayanan S, Cai CY, Assaraf YG. et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat 2020; 48: 100663
• 19 Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14 (03) 451-456
• 20 Baker SJ, Zhang YK, Akama T. et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 2006; 49 (15) 4447-4450
• 21 Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules 2022; 27 (15) 4964
• 22 Uluisik I, Karakaya HC, Koc A. The importance of boron in biological systems. J Trace Elem Med Biol 2018; 45: 156-162
• 23 Leśnikowski ZJ. Recent developments with boron as a platform for novel drug design. Expert Opin Drug Discov 2016; 11 (06) 569-578
• 24 Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci 2013; 1277: 91-104
• 25 Lima LM, Silva BNMD, Barbosa G, Barreiro EJ. β-lactam antibiotics: an overview from a medicinal chemistry perspective. Eur J Med Chem 2020; 208: 112829
• 26 Blumberg PM, Strominger JL. Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol Rev 1974; 38 (03) 291-335
• 27 Typas A, Banzhaf M, Gross CA, Vollmer W. From the regulation of peptidoglycan synthesis to bacterial growth and morphology. Nat Rev Microbiol 2011; 10 (02) 123-136
• 28 Buynak JD. β-Lactamase inhibitors: a review of the patent literature (2010 - 2013). Expert Opin Ther Pat 2013; 23 (11) 1469-1481
• 29 Bonomo RA. β-lactamases: a focus on current challenges. Cold Spring Harb Perspect Med 2017; 7 (01) a025239
• 30 Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis 1988; 10 (04) 677-678
• 31 Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 10 (12, suppl): S122-S129
• 32 Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54 (03) 969-976
• 33 Liu B, Trout REL, Chu GH. et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β-lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem 2020; 63 (06) 2789-2801
• 34 Bassetti M, Ginocchio F, Mikulska M, Taramasso L, Giacobbe DR. Will new antimicrobials overcome resistance among Gram-negatives?. Expert Rev Anti Infect Ther 2011; 9 (10) 909-922
• 35 Bush K. The ABCD's of β-lactamase nomenclature. J Infect Chemother 2013; 19 (04) 549-559
• 36 Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 1995; 39 (12) 2593-2601
• 37 Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nat Rev Microbiol 2019; 17 (05) 295-306
• 38 Falagas ME, Mavroudis AD, Vardakas KZ. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?. Expert Rev Anti Infect Ther 2016; 14 (08) 747-763
• 39 Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors in the clinic. Infect Dis Clin North Am 2016; 30 (02) 441-464
• 40 Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol 2011; 14 (05) 550-555
• 41 Kiener PA, Waley SG. Reversible inhibitors of penicillinases. Biochem J 1978; 169 (01) 197-204
• 42 Beesley T, Gascoyne N, Knott-Hunziker V. et al. The inhibition of class C β-lactamases by boronic acids. Biochem J 1983; 209 (01) 229-233
• 43 Morandi S, Morandi F, Caselli E, Shoichet BK, Prati F. Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors. Bioorg Med Chem 2008; 16 (03) 1195-1205
• 44 Brem J, Cain R, Cahill S. et al. Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun 2016; 7: 12406
• 45 Krajnc A, Brem J, Hinchliffe P. et al. Bicyclic boronate VNRX-5133 inhibits metallo- and serine-β-lactamases. J Med Chem 2019; 62 (18) 8544-8556
• 46 Nocentini A, Supuran CT, Winum JY. Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018). Expert Opin Ther Pat 2018; 28 (06) 493-504
• 47 Hecker SJ, Reddy KR, Totrov M. et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class a serine carbapenemases. J Med Chem 2015; 58 (09) 3682-3692
• 48 Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother 2016; 60 (09) 5454-5458
• 49 Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive enterobacteriaceae. Antimicrob Agents Chemother 2017; 62 (01) e01904-e01917
• 50 Patel TS, Pogue JM, Mills JP, Kaye KS. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. Future Microbiol 2018; 13 (09) 971-983
• 51 Cho JC, Zmarlicka MT, Shaeer KM, Pardo J. Meropenem/vaborbactam, the first carbapenem/β-lactamase inhibitor combination. Ann Pharmacother 2018; 52 (08) 769-779
• 52 Lapuebla A, Abdallah M, Olafisoye O. et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in new york city. Antimicrob Agents Chemother 2015; 59 (08) 4856-4860
• 53 Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae. Antimicrob Agents Chemother 2017; 61 (09) e00567-e17
• 54 Dhillon S. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs 2018; 78 (12) 1259-1270
• 55 Powers RA, Swanson HC, Taracila MA. et al. Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii. Biochemistry 2014; 53 (48) 7670-7679
• 56 Caselli E, Romagnoli C, Powers RA. et al. Inhibition of acinetobacter-derived cephalosporinase: exploring the carboxylate recognition site using novel β-lactamase inhibitors. ACS Infect Dis 2018; 4 (03) 337-348
• 57 Morandi F, Caselli E, Morandi S. et al. Nanomolar inhibitors of AmpC β-lactamase. J Am Chem Soc 2003; 125 (03) 685-695
• 58 Bouza AA, Swanson HC, Smolen KA. et al. Structure-based analysis of boronic acids as inhibitors of acinetobacter-derived cephalosporinase-7, a unique class C β-lactamase. ACS Infect Dis 2018; 4 (03) 325-336
• 59 Werner JP, Mitchell JM, Taracila MA, Bonomo RA, Powers RA. Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase. Protein Sci 2017; 26 (03) 515-526
• 60 Tan Q, Ogawa AM, Painter RE, Park YW, Young K, DiNinno FP. 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived β-lactamase inhibitor with class A, C, and D activity. Bioorg Med Chem Lett 2010; 20 (08) 2622-2624
• 61 McKinney DC, Zhou F, Eyermann CJ. et al. 4,5-Disubstituted 6-aryloxy-1,3-dihydrobenzo[c][1,2]oxaboroles are broad-spectrum serine β-lactamase inhibitors. ACS Infect Dis 2015; 1 (07) 310-316
• 62 Ehmann DE, Jahic H, Ross PL. et al. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem 2013; 288 (39) 27960-27971
• 63 Bush K. Past and present perspectives on β-lactamases. Antimicrob Agents Chemother 2018; 62 (10) e01076-e18
• 64 Hamrick JC, Docquier JD, Uehara T. et al. VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-β-lactamases, restores activity of cefepime in enterobacterales and pseudomonas aeruginosa. Antimicrob Agents Chemother 2020; 64 (03) e01963-e19
• 65 Abdelraouf K, Almarzoky Abuhussain S, Nicolau DP. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria. J Antimicrob Chemother 2020; 75 (12) 3601-3610
• 66 Hecker SJ, Reddy KR, Lomovskaya O. et al. Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-β-lactamases. J Med Chem 2020; 63 (14) 7491-7507
• 67 Lomovskaya O, Nelson K, Rubio-Aparicio D, Tsivkovski R, Sun D, Dudley MN. Impact of intrinsic resistance mechanisms on the potency of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases in enterobacteriaceae, pseudomonas aeruginosa, and acinetobacter baumannii. Antimicrob Agents Chemother 2020; 64 (06) e00552-e20
• 68 Langley GW, Cain R, Tyrrell JM. et al. Profiling interactions of vaborbactam with metallo-β-lactamases. Bioorg Med Chem Lett 2019; 29 (15) 1981-1984
• 69 Tsivkovski R, Totrov M, Lomovskaya O. Biochemical characterization of QPX7728, a new ultrabroad-spectrum β-lactamase inhibitor of serine and metallo-β-lactamases. Antimicrob Agents Chemother 2020; 64 (06) e00130-e20
• 70 Lence E, González-Bello C. Molecular basis of bicyclic boronate β-lactamase inhibitors of ultrabroad efficacy - insights from molecular dynamics simulation studies. Front Microbiol 2021; 12: 721826
• 71 Reddy KR, Parkinson J, Sabet M. et al. Selection of QPX7831, an orally bioavailable prodrug of boronic acid β-lactamase inhibitor QPX7728. J Med Chem 2021; 64 (23) 17523-17529
• 72 Trout RE, Zulli A, Mesaros E. et al. Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): an orally bioavailable β-lactamase inhibitor for enterobacterales expressing ambler class A, C, and D enzymes. J Med Chem 2021; 64 (14) 10155-10166
• 73 Wang YL, Liu S, Yu ZJ. et al. Structure-based development of (1-(3′-mercaptopropanamido)methyl)boronic acid derived broad-spectrum, dual-action inhibitors of metallo- and serine-β-lactamases. J Med Chem 2019; 62 (15) 7160-7184
• 74 Hurdle JG, O'Neill AJ, Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother 2005; 49 (12) 4821-4833
• 75 Pak D, Kim Y, Burton ZF. Aminoacyl-tRNA synthetase evolution and sectoring of the genetic code. Transcription 2018; 9 (04) 205-224
• 76 Bouz G, Zitko J. Inhibitors of aminoacyl-tRNA synthetases as antimycobacterial compounds: an up-to-date review. Bioorg Chem 2021; 110: 104806
• 77 Zhang P, Ma S. Recent development of leucyl-tRNA synthetase inhibitors as antimicrobial agents. MedChemComm 2019; 10 (08) 1329-1341
• 78 Palencia A, Crépin T, Vu MT, Lincecum Jr TL, Martinis SA, Cusack S. Structural dynamics of the aminoacylation and proofreading functional cycle of bacterial leucyl-tRNA synthetase. Nat Struct Mol Biol 2012; 19 (07) 677-684
• 79 Bowers GD, Tenero D, Patel P. et al. Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic. Drug Metab Dispos 2013; 41 (05) 1070-1081
• 80 Palencia A, Liu RJ, Lukarska M. et al. Cryptosporidium and toxoplasma parasites are inhibited by a benzoxaborole targeting leucyl-tRNA synthetase. Antimicrob Agents Chemother 2016; 60 (10) 5817-5827
• 81 Seiradake E, Mao W, Hernandez V. et al. Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles. J Mol Biol 2009; 390 (02) 196-207
• 82 Tandon S, Manhas R, Tiwari N. et al. Deciphering the interaction of benzoxaborole inhibitor AN2690 with connective polypeptide 1 (CP1) editing domain of Leishmania donovani leucyl-tRNA synthetase. J Biosci 2020; 45: 63
• 83 Rock FL, Mao W, Yaremchuk A. et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007; 316 (5832): 1759-1761
• 84 Palencia A, Li X, Bu W. et al. Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase. Antimicrob Agents Chemother 2016; 60 (10) 6271-6280
• 85 Hernandez V, Crépin T, Palencia A. et al. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob Agents Chemother 2013; 57 (03) 1394-1403
• 86 Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 2011; 1241: 122-152
• 87 Purnapatre KP, Rao M, Pandya M. et al. In vitro and in vivo activities of DS86760016, a novel leucyl-tRNA synthetase inhibitor for gram-negative pathogens. Antimicrob Agents Chemother 2018; 62 (04) e01987-e17
• 88 O'Dwyer K, Spivak AT, Ingraham K. et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother 2015; 59 (01) 289-298
• 89 Gupta A, Monteferrante C, Rasina D. et al. A polymorphism in leuS confers reduced susceptibility to GSK2251052 in a clinical isolate of staphylococcus aureus. Antimicrob Agents Chemother 2016; 60 (05) 3219-3221
• 90 Li X, Hernandez V, Rock FL. et al. Discovery of a potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem 2017; 60 (19) 8011-8026
• 91 Hao G, Li H, Yang F. et al. Discovery of benzhydrol-oxaborole derivatives as Streptococcus pneumoniae leucyl-tRNA synthetase inhibitors. Bioorg Med Chem 2021; 29: 115871
• 92 Hu QH, Liu RJ, Fang ZP. et al. Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase. Sci Rep 2013; 3: 2475
• 93 Tan M, Zhu B, Zhou XL. et al. tRNA-dependent pre-transfer editing by prokaryotic leucyl-tRNA synthetase. J Biol Chem 2010; 285 (05) 3235-3244
• 94 Walker GC. Mutagenesis and inducible responses to deoxyribonucleic acid damage in Escherichia coli . Microbiol Rev 1984; 48 (01) 60-93
• 95 Butala M, Zgur-Bertok D, Busby SJ. The bacterial LexA transcriptional repressor. Cell Mol Life Sci 2009; 66 (01) 82-93
• 96 Courcelle J, Khodursky A, Peter B, Brown PO, Hanawalt PC. Comparative gene expression profiles following UV exposure in wild-type and SOS-deficient Escherichia coli . Genetics 2001; 158 (01) 41-64
• 97 Wade JT, Reppas NB, Church GM, Struhl K. Genomic analysis of LexA binding reveals the permissive nature of the Escherichia coli genome and identifies unconventional target sites. Genes Dev 2005; 19 (21) 2619-2630
• 98 Selwood T, Larsen BJ, Mo CY. et al. Advancement of the 5-Amino-1-(carbamoylmethyl)-1H-1,2,3-triazole-4-carboxamide scaffold to disarm the bacterial SOS response. Front Microbiol 2018; 9: 2961
• 99 Myka KK, Marians KJ. Two components of DNA replication-dependent LexA cleavage. J Biol Chem 2020; 295 (30) 10368-10379
• 100 Sassanfar M, Roberts JW. Nature of the SOS-inducing signal in Escherichia coli. The involvement of DNA replication. J Mol Biol 1990; 212 (01) 79-96
• 101 Luo Y, Pfuetzner RA, Mosimann S. et al. Crystal structure of LexA: a conformational switch for regulation of self-cleavage. Cell 2001; 106 (05) 585-594
• 102 Blainey PC, Luo G, Kou SC. et al. Nonspecifically bound proteins spin while diffusing along DNA. Nat Struct Mol Biol 2009; 16 (12) 1224-1229
• 103 Little JW. Mechanism of specific LexA cleavage: autodigestion and the role of RecA coprotease. Biochimie 1991; 73 (04) 411-421
• 104 Okon M, Pfuetzner RA, Vuckovic M, Little JW, Strynadka NC, McIntosh LP. Backbone chemical shift assignments of the LexA catalytic domain in its active conformation. J Biomol NMR 2005; 31 (04) 371-372
• 105 Cirz RT, Jones MB, Gingles NA. et al. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J Bacteriol 2007; 189 (02) 531-539
• 106 Li B, Smith P, Horvath Jr DJ, Romesberg FE, Justice SS. SOS regulatory elements are essential for UPEC pathogenesis. Microbes Infect 2010; 12 (8–9): 662-668
• 107 Mo CY, Culyba MJ, Selwood T. et al. Inhibitors of LexA autoproteolysis and the bacterial SOS response discovered by an academic-industry partnership. ACS Infect Dis 2018; 4 (03) 349-359
• 108 Pagès JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med 2005; 11 (08) 382-389
• 109 Nikaido H, Pagès JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 2012; 36 (02) 340-363
• 110 Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 2015; 28 (02) 337-418
• 111 Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51 (01) 9-11
• 112 Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006; 4 (08) 629-636
• 113 Kuroda T, Tsuchiya T. Multidrug efflux transporters in the MATE family. Biochim Biophys Acta 2009; 1794 (05) 763-768
• 114 Jack DL, Yang NM, Saier Jr MH. The drug/metabolite transporter superfamily. Eur J Biochem 2001; 268 (13) 3620-3639
• 115 Pao SS, Paulsen IT, Saier Jr MH. Major facilitator superfamily. Microbiol Mol Biol Rev 1998; 62 (01) 1-34
• 116 Lubelski J, Konings WN, Driessen AJ. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev 2007; 71 (03) 463-476
• 117 Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta 2009; 1794 (05) 769-781
• 118 Mahmood HY, Jamshidi S, Sutton JM, Rahman KM. Current advances in developing inhibitors of bacterial multidrug efflux pumps. Curr Med Chem 2016; 23 (10) 1062-1081
• 119 Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45 (12) 3375-3380
• 120 Bay DC, Stremick CA, Slipski CJ, Turner RJ. Secondary multidrug efflux pump mutants alter Escherichia coli biofilm growth in the presence of cationic antimicrobial compounds. Res Microbiol 2017; 168 (03) 208-221
• 121 Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. Molecular cloning and characterization of acrA and acrE genes of Escherichia coli . J Bacteriol 1993; 175 (19) 6299-6313
• 122 Moolenaar RL, Crutcher JM, San Joaquin VH. et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission?. Infect Control Hosp Epidemiol 2000; 21 (02) 80-85
• 123 Eaves DJ, Ricci V, Piddock LJ. Expression of acrB, acrF, acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: role in multiple antibiotic resistance. Antimicrob Agents Chemother 2004; 48 (04) 1145-1150
• 124 Nishino K, Latifi T, Groisman EA. Virulence and drug resistance roles of multidrug efflux systems of Salmonella enterica serovar Typhimurium. Mol Microbiol 2006; 59 (01) 126-141
• 125 Willers C, Wentzel JF, du Plessis LH, Gouws C, Hamman JH. Efflux as a mechanism of antimicrobial drug resistance in clinical relevant microorganisms: the role of efflux inhibitors. Expert Opin Ther Targets 2017; 21 (01) 23-36
• 126 Costa SS, Viveiros M, Amaral L, Couto I. Multidrug efflux pumps in Staphylococcus aureus: an update. Open Microbiol J 2013; 7: 59-71
• 127 Jang S. Multidrug efflux pumps in Staphylococcus aureus and their clinical implications. J Microbiol 2016; 54 (01) 1-8
• 128 Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae . Antimicrob Agents Chemother 1999; 43 (01) 187-189
• 129 Serçinoğlu O, Senturk D, Altinisik Kaya FE. et al. Identification of novel inhibitors of the ABC transporter BmrA. Bioorg Chem 2020; 105: 104452
• 130 Lacabanne D, Orelle C, Lecoq L. et al. Flexible-to-rigid transition is central for substrate transport in the ABC transporter BmrA from Bacillus subtilis . Commun Biol 2019; 2: 149
• 131 Choudhuri BS, Bhakta S, Barik R, Basu J, Kundu M, Chakrabarti P. Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis . Biochem J 2002; 367 (Pt 1): 279-285
• 132 Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64 (02) 159-204
• 133 Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2: 65
• 134 Wang Y, Venter H, Ma S. Efflux pump inhibitors: a novel approach to combat efflux-mediated drug resistance in bacteria. Curr Drug Targets 2016; 17 (06) 702-719
• 135 Lomovskaya O, Warren MS, Lee A. et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45 (01) 105-116
• 136 Yu EW, Aires JR, Nikaido H. AcrB multidrug efflux pump of Escherichia coli: composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. J Bacteriol 2003; 185 (19) 5657-5664
• 137 Otto M. Community-associated MRSA: what makes them special?. Int J Med Microbiol 2013; 303 (6–7): 324-330
• 138 Craft KM, Nguyen JM, Berg LJ, Townsend SD. Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype. MedChemComm 2019; 10 (08) 1231-1241
• 139 Brawley DN, Sauer DB, Li J. et al. Structural basis for inhibition of the drug efflux pump NorA from Staphylococcus aureus . Nat Chem Biol 2022; 18 (07) 706-712
• 140 Fontaine F, Hequet A, Voisin-Chiret AS. et al. First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump. J Med Chem 2014; 57 (06) 2536-2548
• 141 Fontaine F, Héquet A, Voisin-Chiret AS. et al. Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives. Eur J Med Chem 2015; 95: 185-198
• 142 Nielsen FH. Update on human health effects of boron. J Trace Elem Med Biol 2014; 28 (04) 383-387
• 143 Adachi S, Cognetta III AB, Niphakis MJ. et al. Facile synthesis of borofragments and their evaluation in activity-based protein profiling. Chem Commun (Camb) 2015; 51 (17) 3608-3611
• 144 António JPM, Russo R, Carvalho CP, Cal PMSD, Gois PMP. Boronic acids as building blocks for the construction of therapeutically useful bioconjugates. Chem Soc Rev 2019; 48 (13) 3513-3536